'Reassessment of Performance and Pipeline' from Day One
Samsung Biologics as a 'Pure CDMO'
Samsung Epi Holdings to 'Expand Drug Development and Investment'

Samsung Biologics and Samsung Episholdings were simultaneously relisted on the KOSPI market on November 24, with a combined market capitalization of 91 trillion won. The market has generally responded positively to the spin-off of Samsung Biologics, which has now acquired a new growth engine through investments in new drug development and the bio ecosystem.


As of 10 a.m. on the 24th, Samsung Biologics was trading at 1.7 million won, while Samsung Episholdings was trading at 497,000 won. Their respective market capitalizations stood at approximately 78.7 trillion won and 12.3 trillion won. The combined market capitalization of the two stocks reached about 91 trillion won, an increase of around 4 trillion won compared to the pre-spin-off market cap of 86.9 trillion won.


Samsung Biologics Relists as Two Stocks... Combined Market Cap Reaches 91 Trillion Won View original image

Applying a 65-to-35 ratio based on net asset value, Samsung Biologics was valued at about 56.5 trillion won, while the newly established Samsung Episholdings was valued at about 30.4 trillion won. Companies relisted after a spin-off can experience unlimited price fluctuations during the single-price trading session held from 8:30 to 9:00 a.m. before the market opens. During this session, Samsung Biologics surged by 47.18% to 1,841,000 won, debuting with a market capitalization of 85 trillion won. Samsung Episholdings, however, was listed with a market capitalization of about 15 trillion won, roughly 50% lower than the initial valuation based on the spin-off ratio. The market appears to have placed a high premium on the stability of Samsung Biologics. In contrast, analysis suggests that Samsung Episholdings was primarily evaluated based on the value of its subsidiary Samsung Bioepis’s biosimilar business. The initial assessment seems to have deferred the valuation of new business areas such as new drug development.


Samsung Biologics currently boasts the world’s largest single-site antibody drug production capacity among global contract development and manufacturing organizations (CDMOs), with a total of 780,000 liters. Plants 1 through 4 account for 604,000 liters, and this year, Plant 5 began operations with a capacity of 180,000 liters. Once Plants 6 through 8 are completed by 2032, total production capacity will reach 1,324,000 liters, creating an unrivaled “super-gap” compared to other CDMOs. Industry experts believe that if Samsung Biologics secures a production base in the United States, which is currently under consideration, its supply chain competitiveness to handle long-term, large-scale orders from global clients will be further strengthened. In particular, the “full-cycle CRDMO model,” which integrates contract development (CDO), contract manufacturing (CMO), and contract research (CRO) services into a single system, has rapidly expanded the company’s client base over the past three years and serves as the foundation for Samsung Biologics’s external growth. With the spin-off resolving internal conflicts of interest, there is now a greater possibility of expanding contracts with major global pharmaceutical companies in the future.


Samsung Episholdings aims to serve as a “domestic big pharma platform” dedicated to new drugs, investments, and open innovation. Rather than relying on a single therapeutic area, the company seeks to foster active internal collaboration within the ecosystem to continuously generate diverse drug candidates. To this end, Samsung Episholdings has made Samsung Bioepis a wholly owned subsidiary and established “EpisNextLab” as a subsidiary to drive new growth in the bio sector. Through an open innovation strategy that identifies and collaborates with biotech firms possessing promising technologies, the company plans to secure a next-generation new drug pipeline.


The market capitalization structure on the first day of relisting reflects the impact of this strategic separation. Samsung Biologics has reaffirmed its stability based on performance in a high-growth industry, while Samsung Episholdings now faces the challenge of how quickly it can realize its growth potential in new drugs, antibody-drug conjugates (ADC), and an investment ecosystem, in addition to its existing biosimilar revenues.



Samsung Biologics Relists as Two Stocks... Combined Market Cap Reaches 91 Trillion Won View original image

Jung Yuntaek, Director of the Pharmaceutical Industry Strategy Research Institute, stated, “As Samsung Biologics continues to strengthen its existing capabilities in production and contract orders as a CDMO, the evaluation of Samsung Episholdings will depend on which new drug pipelines it secures and the investment outcomes it achieves.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing